Biogen Inc. (BIIB)

NASDAQ: BIIB · IEX Real-Time Price · USD
215.63
-0.71 (-0.33%)
At close: Mar 28, 2024, 4:00 PM
215.50
-0.13 (-0.06%)
After-hours: Mar 28, 2024, 7:46 PM EDT

Company Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development.

It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.
Biogen logo
Country United States
Founded 1978
IPO Date Sep 16, 1991
Industry Drug Manufacturers - General
Sector Healthcare
Employees 7,570
CEO Christopher A. Viehbacher

Contact Details

Address:
225 Binney Street
Cambridge, Massachusetts 02142
United States
Phone (781) 464-2000
Website biogen.com

Stock Details

Ticker Symbol BIIB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000875045
CUSIP Number 09062X103
ISIN Number US09062X1037
Employer ID 33-0112644
SIC Code 2836

Key Executives

Name Position
Christopher A. Viehbacher President, Chief Executive Officer and Director
Michael R. McDonnell CPA Executive Vice President and Chief Financial Officer
Nicole Murphy Head of Pharmaceutical Operations and Technology
Susan H. Alexander Esq. Executive Vice President and Chief Legal Officer
Dr. Ginger Gregory Executive Vice President and Chief Human Resources Officer
Robin C. Kramer Senior Vice President and Chief Accounting Officer
Charles E. Triano Senior Vice President and Head of Investor Relations
Natacha Gassenbach Chief Communication Officer and Head of Corporate Affairs
Adam Keeney Ph.D. Executive Vice President and Head of Corporate Development
Alisha A. Alaimo President and Head of North America

Latest SEC Filings

Date Type Title
Feb 22, 2024 144 Filing
Feb 21, 2024 144 Filing
Feb 14, 2024 10-K Annual Report
Feb 13, 2024 8-K Current Report
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 144 Filing
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 144 Filing
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals